This talk will set the discussion and outline current testing of drugs and how our approaches may have been limiting and inadequate. Did traditional trial endpoints terminate drugs that should have succeeded? Could genomics or alternative endpoints have impacted clinical trial design?
Stanford University School of Medicine
You must be logged in and own this session in order to